|
1
|
Hegedüs L: Thyroid ultrasonography as a
screening tool for thyroid disease. Thyroid. 14:879–880. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gharib H and Papini E: Thyroid nodules:
Clinical importance, assessment and treatment. Endocrinol Metab
Clin North Am. 36707–735. (vi)2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Williams ED: Guest editorial: Two
proposals regarding the terminology of thyroid tumors. Int J Surg
Pathol. 8:181–183. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu Z, Li X, Shi L, Maimaiti Y, Chen T, Li
Z, Wang S, Xiong Y, Guo H, He W, et al: Cytokeratin 19,
thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive
behavior of papillary thyroid carcinoma. Int J Clin Exp Med.
7:2304–2308. 2014.PubMed/NCBI
|
|
5
|
Flanagan JN, Pineda P, Knapp PE, De Las
Morenas A, Lee SL and Braverman LE: Expression of cytokeratin 19 in
the diagnosis of thyroid papillary carcinoma by quantitative
polymerase chain reaction. Endocr Pract. 14:168–174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Krzeslak A, Gaj Z, Pomorski L and Lipinska
A: Expression of cytokeratin 19 in the cytosolic fraction of
thyroid lesions: ELISA and western blot analysis. Mol Med Rep.
1:565–569. 2008.PubMed/NCBI
|
|
7
|
Sumana BS, Shashidhar S and Shivarudrappa
AS: Galectin-3 immunohistochemical expression in thyroid neoplasms.
J Clin Diagn Res. 9:EC07–EC11. 2015.PubMed/NCBI
|
|
8
|
Bartolazzi A, Gasbarri A, Papotti M,
Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orlandi F,
Nardi F, et al: Application of an immunodiagnostic method for
improving preoperative diagnosis of nodular thyroid lesions.
Lancet. 357:1644–1650. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Inohara H, Honjo Y, Yoshii T, Akahani S,
Yoshida J, Hattori K, Okamoto S, Sawada T, Raz A and Kubo T:
Expression of galectin-3 in fine-needle aspirates as a diagnostic
marker differentiating benign from malignant thyroid neoplasms.
Cancer. 85:2475–2484. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gasbarri A, Martegani MP, Del Prete F,
Lucante T, Natali PG and Bartolazzi A: Galectin-3 and CD44v6
isoforms in the preoperative evaluation of thyroid nodules. J Clin
Oncol. 17:3494–3502. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carpi A, Rossi G, Coscio GD, Iervasi G,
Nicolini A, Carpi F, Mechanick JI and Bartolazzi A: Galectin-3
detection on large-needle aspiration biopsy improves preoperative
selection of thyroid nodules: A prospective cohort study. Ann Med.
42:70–78. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu Z, Yu P, Xiong Y, Zeng W, Li X,
Maiaiti Y, Wang S, Song H, Shi L, Liu C, et al: Significance of
CK19, TPO, and HBME-1 expression for diagnosis of papillary thyroid
carcinoma. Int J Clin Exp Med. 8:4369–4374. 2015.PubMed/NCBI
|
|
13
|
Mataraci EA, Ozgüven BY and Kabukçuoglu F:
Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic
and nonneoplastic thyroid lesions. Pol J Pathol. 63:58–64.
2012.PubMed/NCBI
|
|
14
|
Schmitt AC, Cohen C and Siddiqui MT:
Paired box gene 8, HBME-1, and cytokeratin 19 expression in
preoperative fine-needle aspiration of papillary thyroid carcinoma:
Diagnostic utility. Cancer Cytopathol. 118:196–202. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Niedziela M, Maceluch J and Korman E:
Galectin-3 is not an universal marker of malignancy in thyroid
nodular disease in children and adolescents. J Clin Endocrinol
Metab. 87:4411–4415. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mehrotra P, Okpokam A, Bouhaidar R,
Johnson SJ, Wilson JA, Davies BR and Lennard TW: Galectin-3 does
not reliably distinguish benign from malignant thyroid neoplasms.
Histopathology. 45:493–500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mills LJ, Poller DN and Yiangou C:
Galectin-3 is not useful in thyroid FNA. Cytopathology. 16:132–138.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Park YJ, Kwak SH, Kim DC, Kim H, Choe G,
Park DJ, Jang HC, Park SH, Cho BY and Park SY: Diagnostic value of
galectin-3, HBME-1, cytokeratin 19, high molecular weight
cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis
of thyroid nodules. J Korean Med Sci. 22:621–628. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu X, Sun T, Lu H, Zhou X, Lu Y, Cai X
and Zhu X: Diagnostic significance of CK19, RET, galectin-3 and
HBME-1 expression for papillary thyroid carcinoma. J Clin Pathol.
63:786–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Barroeta JE, Baloch ZW, Lal P, Pasha TL,
Zhang PJ and LiVolsi VA: Diagnostic value of differential
expression of CK19, Galectin-3, HBME-1, ERK, RET and p16 in benign
and malignant follicular-derived lesions of the thyroid: An
immunohistochemical tissue microarray analysis. Endocr Pathol.
17:225–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Danguy A, Camby I and Kiss R: Galectins
and cancer. Biochim Biophys Acta. 1572:285–293. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Demydenko D and Berest I: Expression of
galectin-1 in malignant tumors. Exp Oncol. 31:74–79.
2009.PubMed/NCBI
|
|
23
|
Balan V, Nangia-Makker P and Raz A:
Galectins as cancer biomarkers. Cancers (Basel). 2:592–610. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Smetana K Jr, André S, Kaltner H, Kopitz J
and Gabius HJ: Context-dependent multifunctionality of galectin-1:
A challenge for defining the lectin as therapeutic target. Expert
Opin Ther Targets. 17:379–392. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chiariotti L, Berlingieri MT, Battaglia C,
Benvenuto G, Martelli ML, Salvatore P, Chiappetta G, Bruni CB and
Fusco A: Expression of galectin-1 in normal human thyroid gland and
in differentiated and poorly differentiated thyroid tumors. Int J
Cancer. 64:171–175. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu XC, el-Naggar AK and Lotan R:
Differential expression of galectin-1 and galectin-3 in thyroid
tumors. Potential diagnostic implications. Am J Pathol.
147:815–822. 1995.PubMed/NCBI
|
|
27
|
Salajegheh A, Dolan-Evans E, Sullivan E,
Irani S, Rahman MA, Vosgha H, Gopalan V, Smith RA and Lam AK: The
expression profiles of the galectin gene family in primary and
metastatic papillary thyroid carcinoma with particular emphasis on
galectin-1 and galectin-3 expression. Exp Mol Pathol. 96:212–218.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Torres-Cabala C, Bibbo M, Panizo-Santos A,
Barazi H, Krutzsch H, Roberts DD and Merino MJ: Proteomic
identification of new biomarkers and application in thyroid
cytology. Acta Cytol. 50:518–528. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Paron I, D'Ambrosio C, Scaloni A,
Berlingieri MT, Pallante PL, Fusco A, Bivi N, Tell G and Damante G:
A differential proteomic approach to identify proteins associated
with thyroid cell transformation. J Mol Endocrinol. 34:199–207.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saussez S, Glinoer D, Chantrain G, Pattou
F, Carnaille B, André S, Gabius HJ and Laurent G: Serum galectin-1
and galectin-3 levels in benign and malignant nodular thyroid
disease. Thyroid. 18:705–712. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sanchez-Ruderisch H, Fischer C, Detjen KM,
Welzel M, Wimmel A, Manning JC, André S and Gabius HJ: Tumor
suppressor p16 INK4a: Downregulation of galectin-3, an endogenous
competitor of the pro-anoikis effector galectin-1, in a pancreatic
carcinoma model. FEBS J. 277:3552–3563. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Weinmann D, Schlangen K, André S, Schmidt
S, Walzer SM, Kubista B, Windhager R, Toegel S and Gabius HJ:
Galectin-3 induces a pro-degradative/inflammatory gene signature in
human chondrocytes, teaming up with galectin-1 in osteoarthritis
pathogenesis. Sci Rep. 6:391122016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Verhulst P, Devos P, Aubert S, Buob D,
Cranshaw I, Do Cao C, Pattou F, Carnaille B, Wemeau JL and
Leteurtre E: A score based on microscopic criteria proposed for
analysis of papillary carcinoma of the thyroid. Virchows Arch.
452:233–240. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Toegel S, Bieder D, André S, Kayser K,
Walzer SM, Hobusch G, Windhager R and Gabius HJ: Human
osteoarthritic knee cartilage: Fingerprinting of
adhesion/growth-regulatory galectins in vitro and in situ indicates
differential upregulation in severe degeneration. Histochem Cell
Biol. 142:373–388. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kaltner H, Seyrek K, Heck A, Sinowatz F
and Gabius HJ: Galectin-1 and galectin-3 in fetal development of
bovine respiratory and digestive tracts. Comparison of cell
type-specific expression profiles and subcellular localization.
Cell Tissue Res. 307:35–46. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Langbein S, Brade J, Badawi JK, Hatzinger
M, Kaltner H, Lensch M, Specht K, André S, Brinck U, Alken P and
Gabius HJ: Gene-expression signature of adhesion/growth-regulatory
tissue lectins (galectins) in transitional cell cancer and its
prognostic relevance. Histopathology. 51:681–690. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Danguy A, Rorive S, Decaestecker C,
Bronckart Y, Kaltner H, Hadari YR, Goren R, Zich Y, Petein M,
Salmon I, et al: Immunohistochemical profile of galectin-8
expression in benign and malignant tumors of epithelial,
mesenchymatous and adipous origins, and of the nervous system.
Histol Histopathol. 16:861–868. 2001.PubMed/NCBI
|
|
38
|
Saiselet M, Floor S, Tarabichi M, Dom G,
Hébrant A, van Staveren WC and Maenhaut C: Thyroid cancer cell
lines: An overview. Front Endocrinol (Lausanne).
3:1332012.PubMed/NCBI
|
|
39
|
Kopitz J, Vértesy S, André S, Fiedler S,
Schnölzer M and Gabius HJ: Human chimera-type galectin-3: Defining
the critical tail length for high-affinity glycoprotein/cell
surface binding and functional competition with galectin-1 in
neuroblastoma cell growth regulation. Biochimie. 104:90–99. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ippel H, Miller MC, Vértesy S, Zheng Y,
Cañada FJ, Suylen D, Umemoto K, Romanò C, Hackeng T, Tai G, et al:
Intra- and intermolecular interactions of human galectin-3:
Assessment by full-assignment-based NMR. Glycobiology. 26:888–903.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rigau V, Martel B, Evrard C, Rousselot P
and Galateau-Salle F: HBME-1 immunostaining in thyroid pathology.
Ann Pathol. 21:15–20. 2001.(In French). PubMed/NCBI
|
|
42
|
Prasad ML, Pellegata NS, Huang Y, Nagaraja
HN, de la Chapelle A and Kloos RT: Galectin-3, fibronectin-1,
CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful
for the differential diagnosis of thyroid tumors. Mod Pathol.
18:48–57. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu YY, Morreau H, Kievit J, Romijn JA,
Carrasco N and Smit JW: Combined immunostaining with galectin-3,
fibronectin-1, CITED-1, Hector Battifora mesothelial-1,
cytokeratin-19, peroxisome proliferator-activated receptor-{gamma},
and sodium/iodide symporter antibodies for the differential
diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol.
158:375–384. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
De Micco C, Savchenko V, Giorgi R, Sebag F
and Henry JF: Utility of malignancy markers in fine-needle
aspiration cytology of thyroid nodules: Comparison of Hector
Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl
aminopeptidase IV. Br J Cancer. 98:818–823. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
De Micco C, Ruf J, Chrestian MA, Gros N,
Henry JF and Carayon P: Immunohistochemical study of thyroid
peroxidase in normal, hyperplastic, and neoplastic human thyroid
tissues. Cancer. 67:3036–3041. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Faggiano A, Caillou B, Lacroix L, Talbot
M, Filetti S, Bidart JM and Schlumberger M: Functional
characterization of human thyroid tissue with immunohistochemistry.
Thyroid. 17:203–211. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Weber KB, Shroyer KR, Heinz DE, Nawaz S,
Said MS and Haugen BR: The use of a combination of galectin-3 and
thyroid peroxidase for the diagnosis and prognosis of thyroid
cancer. Am J Clin Pathol. 122:524–531. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
de Matos LL, Del Giglio AB, Matsubayashi
CO, de Lima Farah M, Del Giglio A and da Silva Pinhal MA:
Expression of CK-19, galectin-3 and HBME-1 in the differentiation
of thyroid lesions: Systematic review and diagnostic meta-analysis.
Diagn Pathol. 7:972012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dunđerović D, Lipkovski JM, Boričic I,
Soldatović I, Božic V, Cvejić D and Tatić S: Defining the value of
CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell
derived lesions of thyroid with systematic review of literature.
Diagn Pathol. 10:1962015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
de Matos PS, Ferreira AP, de Oliveira
Facuri F, Assumpção LV, Metze K and Ward LS: Usefulness of HBME-1,
cytokeratin 19 and galectin-3 immunostaining in the diagnosis of
thyroid malignancy. Histopathology. 47:391–401. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cheung CC, Ezzat S, Freeman JL, Rosen IB
and Asa SL: Immunohistochemical diagnosis of papillary thyroid
carcinoma. Mod Pathol. 14:338–342. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kaltner H, Toegel S, Caballero GG, Manning
JC, Ledeen RW and Gabius HJ: Galectins: Their network and roles in
immunity/tumor growth control. Histochem Cell Biol. 147:239–256.
2017. View Article : Google Scholar : PubMed/NCBI
|
